NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/23/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization883.11 mln
Float129 mln
Earnings Date08/17/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
14.88
Transformational upside
Relative Strength
16
/ 100
Significantly lagging
Debt / Equity
0.12
Very low leverage
ROE
-96.27
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Annexon Inc. is a clinical-stage biopharmaceutical company founded in 2011 and based in Brisbane, California, focused on developing treatments for inflammatory and autoimmune diseases. Its lead drug candidate, Tanruprubart, is currently being tested in late-stage trials for Guillain-Barré syndrome and earlier-stage trials for Huntington's disease and ALS. The company's pipeline also includes ANX007, in Phase 3 development for geographic atrophy, as well as an oral drug and an antibody fragment targeting autoimmune conditions such as lupus nephritis.
